Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas.

Molecules (Basel, Switzerland) - 23 Mar 2023

Neumaier Felix, Zlatopolskiy Boris D, Neumaier Bernd

Abstract excerpt

Gliomas are the most common primary brain tumors in adults. A diffuse infiltrative growth pattern and high resistance to therapy make them largely incurable, but there are significant differences in the prognosis of patients with different subtypes of glioma. Mutations in isocitrate dehydrogenase (IDH) have been recognized as an important biomarker for glioma classification and a potential therapeutic target....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioma
Share to Isocitrate Dehydrogenase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Positron-Emission Tomography

Source

Open in PubMed Open full text

Identifiers

PMID: 37049661
DOI: 10.3390/molecules28072890
PMCID: PMC10096429

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas.PMID 37049661Read ↗

Therapies for IDH-Mutant Gliomas.Semantic proximity Read ↗

Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas.Semantic proximity Read ↗

Targeting IDH1/IDH2 mutations in gliomas.Semantic proximity Read ↗

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.Semantic proximity Read ↗

Preparation and Preclinical Evaluation of 18F-Labeled Olutasidenib Derivatives for Non-Invasive Detection of Mutated Isocitrate Dehydrogenase 1 (mIDH1).Semantic proximity Read ↗

Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma.Semantic proximity Read ↗

Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.Semantic proximity Read ↗

State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond.Semantic proximity Read ↗

The Role of Mutant IDH Inhibitors in the Treatment of Glioma.Semantic proximity Read ↗

Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors.Semantic proximity Read ↗

Treatment of IDH-mutant glioma in the INDIGO eraSemantic proximity Read ↗

IDH1 and IDH2 mutations in gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.